Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.

Trial Profile

Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Ivermectin (Primary) ; Metronidazole
  • Indications Bacterial infections; Rosacea
  • Focus Therapeutic Use
  • Acronyms ATTRACT
  • Sponsors Galderma
  • Most Recent Events

    • 01 Sep 2016 Results (n=161) of a post-hoc subanalysis comparing Ivermectin 1% cream with metronidazole 0.75% in the treatment of severe inflammatory lesions of rosacea, published in the Dermatology and Therapy.
    • 27 Mar 2015 According to a Gladerma media release, ivermectin cream received a positive outcome by European Decentralised Procedure for Approval. The Marketing Authorization application was based on this and other two phase III trials.
    • 27 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top